Treatment and risk in heart failure gaps in evidence or quality?

Circulation: Cardiovascular Quality and Outcomes

Volumn 3, Issue 3, 2010, Pages 309-315

  Peterson, Pamela N ^a,b,c   Rumsfeld, John S ^b,c,f   Liang, Li ^d   Hernandez, Adrian F ^d   Peterson, Eric D ^d   Fonarow, Gregg C ^e   Masoudi, Frederick A ^a,b,c  

^a DENVER HEALTH MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c KAISER PERMANENTE   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Health policy and outcomes research; Heart failure; Pharmacotherapy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG USE; EVIDENCE BASED PRACTICE; FEMALE; HEALTH CARE QUALITY; HEALTH PROGRAM; HEART LEFT VENTRICLE FAILURE; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT CODING; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTOLIC DYSFUNCTION; AGE; AGED; ANCESTRY GROUP; COMPARATIVE STUDY; COMPLICATION; CONTRAINDICATIONS; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; PRACTICE GUIDELINE; SURVIVAL; VERY ELDERLY;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CONTINENTAL POPULATION GROUPS; EVIDENCE-BASED PRACTICE; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PATIENT DISCHARGE; PRACTICE GUIDELINES AS TOPIC; QUALITY OF HEALTH CARE; RISK ASSESSMENT; SURVIVAL ANALYSIS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77953390121     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.109.879478     Document Type: Article

References (29)

1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult-Summary Article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:1825-1852.
2. Bonow RO, Bennett S, Casey DEJ, Ganiats TG, Hlatky MA, Konstam MA, Lambrew CT, Normand SL, Pina IL, Radford MJ, Smith AL, Stevenson LW, Bonow RO, Bennett SJ, Burke G, Eagle KA, Krumholz HM, Lambrew CT, Linderbaum J, Masoudi FA, Normand SL, Ritchie JL, Rumsfeld JS, Spertus JA. ACC/AHA Clinical Performance Measures for Adults With Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society of America. Circulation. 2005;112:1853-1887. (Pubitemid 41368160)
3. Hospital Compare Website. Available at: http://www.hospitalcompare. hhs.gov. Accessed September 24, 2009.
4. Hong Y, LaBresh KA. Overview of the American Heart Association "Get With The Guidelines" programs: coronary heart disease, stroke, and heart failure. Crit Pathw Cardiol. 2006;5:179-186.
5. Cohen-Solal A, McMurray JJ, Swedberg K, Pfeffer MA, Puu M, Solomon SD, Michelson EL, Yusuf S, Granger CB, CHARM I. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity programme. Eur Heart J. 2008;29:3022-3028.
6. Meredith PA, Ostergren J, Anand I, Puu M, Solomon SD, Michelson EL, Olofsson B, Granger CB, Yusuf S, Swedberg K, Pfeffer MA, McMurray JJ. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. J Am Coll Cardiol. 2008;52:2000-2007.
7. Lee DS, Tu JV, Juurlink DN, Alter DA, Ko DT, Austin PC, Chong A, Stukel TA, Levy D, Laupacis A. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA. 2005;294:1240-1247.
8. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA. 2004;291:1864-1870.
9. Yan AT, Yan RT, Tan M, Fung A, Cohen EA, Fitchett DH, Langer A, Goodman SG, Canadian Acute CS. Management patterns in relation to risk stratification among patients with non-ST elevation acute coronary syndromes. Arch Intern Med. 2007;167:1009-1016.
10. McAlister FA, Oreopoulos A, Norris CM, Graham MM, Tsuyuki RT, Knudtson M, Ghali WA, Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators: exploring the treatment-risk paradox in coronary disease. Arch Intern Med. 2007;167:1019-1025.
11. Hernandez AF, Fonarow GC, Liang L, Al Khatib SM, Curtis LH, LaBresh KA, Yancy CW, Albert NM, Peterson ED. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA. 2007;298:1525-1532.
12. Peterson PN, Rumsfeld JS, Liang L, Albert NM, Hernandez AF, Peterson ED, Fonarow GC, Masoudi FA, on behalf of the American Heart Association Get With the Guidelines-Heart Failure Program. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association Get With the Guidelines Program. Circ Cardiovasc Qual Outcomes. 2010;3:25-32.
13. Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC Jr. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA. 2009;301:831-841.
14. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
15. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions [erratum appears in N Engl J Med 1992;327:1768].
16. N Engl J Med. 1992;327:685-691.
17. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial: the SAVE Investigators N Engl J Med. 1992;327:669-677.
18. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
19. Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, Krumholz HM. National patterns of use and effectiveness of angiotensin converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation. 2004;110:724-731.
20. Ahmed A, Kiefe CI, Allman RM, Sims RV, DeLong JF. Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc. 2002;50:1659-1666. (Pubitemid 35192537)
21. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation. 2004;109:1004-1009.
22. Berger AK, Duval S, Manske C, Vazquez G, Barber C, Miller L, Luepker RV. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Am Heart J. 2007;153:1064-1073.
23. Spertus JA, Furman MI. Translating evidence into practice: are we neglecting the neediest? Arch Intern Med. 2007;167:987-988.
24. Yan AT, Yan RT, Huynh T, Casanova A, Raimondo FE, Fitchett DH, Langer A, Goodman SG, Canadian Acute Coronary Syndrome Registry. Understanding physicians' risk stratification of acute coronary syndromes: insights from the Canadian ACS 2 Registry. Arch Intern Med. 2009;169:372-378.
25. Fonarow GC, Yancy CW, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, Mehra M, O'Connor CM, Reynolds D, Walsh MN. Improving the use of evidence-based heart failure therapies in the outpatient setting: the IMPROVE HF performance improvement registry. Am Heart J. 2007;154:12-38.
26. Mehta RH, Liang L, Karve AM, Hernandez AF, Rumsfeld JS, Fonarow GC, Peterson ED. Association of patient case-mix adjustment: hospital process performance rankings, and eligibility for financial incentives. JAMA. 2008;300:1897-1903.
27. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581-2587.
28. O'Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M, Greenberg BH, Yancy CW, Young JB, Fonarow GC. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2008;156:662-673.
29. Butler J, Arbogast PG, Daugherty J, Jain MK, Ray WA, Griffin MR. Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. J Am Coll Cardiol. 2004;43:2036-2043.